- Robert Tessarolo will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference
- The conference, to be held virtually from May 4-6, will unite the top business and academic leaders
- Robert will be speaking on the use of psychedelics in treating obesity and eating disorders
- NeonMind is currently advancing two psilocybin-based drug development programs aimed at treating obesity
- NeonMind is engaged in the research and development of products to optimize human health and performance
- NeonMind Biosciences (NEON) opened trading at C$0.23 per share
NeonMind Biosciences President & CEO will speak at the Psychedelic, Therapeutics, & Drug Development Conference.
He will be speaking on the use of psychedelics in treating obesity and eating disorders.
The conference, being held virtually from May 4-6, will unite the top business and academic leaders including Frederick Barrett, Ph.D., Assistant Professor of Psychiatry & Behavioral Sciences at Johns Hopkins School of Medicine, to discuss, analyze, and share intelligence on regulatory changes and other challenges on psychedelic research for the treatment of a myriad of serious chronic medical conditions.
“The Psychedelic, Therapeutics, and Drug Development Conference is an excellent opportunity for NeonMind to share our vision and progress with other industry leaders and key stakeholders,” said Rob Tessarolo.
“I also look forward to listening to the many great experts and innovators who will discuss a number of regulatory and policy changes that will help unlock the full health potential of this emerging field.”
NeonMind is currently advancing two psilocybin-based drug development programs aimed at treating obesity.
Psychedelic therapy has the potential to institute long-term positive behaviours that may aid in weight loss and its maintenance, and psilocybin in low doses may help control appetite and satiety.
“There is a clear need for new treatments, new solutions, new approaches for the obesity epidemic and psychedelics are well-positioned to offer new therapeutic breakthroughs,” said Rob Tessarolo.
“NeonMind will continue to advance our important research and be a leader in commercialization following regulatory approval.”
NeonMind is engaged in the research and development of products to optimize human health and performance.
NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom-infused products.
NeonMind Biosciences (NEON) opened trading at C$0.23 per share.